Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank

Scotiabank raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $51 from $50 and keeps an Outperform rating on the shares. The company provided “a slew of positive updates,” which included an announcement of updated phase 1 data for RP-A501, the analyst tells investors. Rocket continues to have positive momentum with the potential to have multiple marketed products within the next 12 months, the firm adds.